




Tackling antibiotic resistance together


TUBERCULOSIS & NTM



GRAM-NEGATIVES



CAPABILITY BUILDING



98

Participants

489

M€ Budget

9

Projects



13+

Programmes

10 new preclinical candidates and
5 Phase II-ready assets by 2025

www.amr-accelerator.eu

Projects in the AMR Accelerator



IMI Associated Partners for ERA4TB



IMI Associated Partners for UNITE4TB



innovative medicines initiative



www.imi.europa.eu

The AMR Accelerator projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853976 | 853967 | 853979 | 853932 | 853903 | 853800 | 853989 | 101007873 | 101034420. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. ERA4TB has received additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.